Every September, the European patient umbrella organisation EU-PFF leads the Pulmonary Fibrosis Awareness Month, designed to shine a light on the realities of pulmonary fibrosis (IPF), a serious and life-limiting condition. It is a progressive, irreversible, chronic lung disease causing scarring of the lung tissue with presently no cure. Symptoms include shortness of breath, persistent cough and fatigue. Patients are in great need of more effective and tolerable treatments as well as earlier and more accurate diagnoses. The “Breathing Life” campaign has also a special focus on the importance of ensuring that all patients that need supplementary oxygen receives it, regardless of geography, policy or health system limitations.
The ultimate treatment goal is to halt the disease, or ideally reverse the lung scarring. Oxcia’s OXC-201 has a novel mechanism, targeting the underlying processes in fibrotic lung disease and has potential to halt the disease progression, improve lung function and prevent further lung damage. In February 2023, the EIC (European Innovation Council) awarded Oxcia AB a grant of 2.5 million euros for OXC-201 and the project TOPFIBRO within the EIC-Transition program. This finances the ongoing pre-clinical work and the start of phase 1. More information is available at https://topfibro.oxcia.eu/
